Blincyto (blinatumomab) / Astellas, Amgen 
Welcome,         Profile    Billing    Logout  
 29 Diseases   78 Trials   78 Trials   3560 News 


«12...7891011121314151617...4445»
  • ||||||||||  Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Ph+ ALL in 2022: is there an optimal approach? (Pubmed Central) -  Dec 10, 2022   
    With improvements in TKI efficacy and allogeneic hematopoietic cell transplantation (HCT), survival has improved over the past 3 decades, and the role of chemotherapy and allogeneic HCT is now changing. Better risk stratification, the application of the third-generation TKI ponatinib, and the use of immunotherapy with the CD19-CD3 bifunctional T-cell engaging antibody blinatumomab in place of chemotherapy has made therapy for Ph+ ALL more tolerable and arguably more efficacious, especially for older patients who comprise most patients with Ph+ ALL.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen
    Journal, IO biomarker:  Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy. (Pubmed Central) -  Dec 10, 2022   
    In contrast, infants with KMT2A-germline ALL have demonstrated excellent survival outcomes with current therapy, but there remains a high burden of treatment-related morbidity. Greater understanding of the underlying blast genetics for infants with KMT2A-germline ALL and incorporation of immunotherapeutic approaches may enable a reduction in the intensity of chemotherapy while maintaining the excellent outcomes.
  • ||||||||||  Scemblix (asciminib) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen
    Enrollment closed, Combination therapy:  ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML (clinicaltrials.gov) -  Dec 6, 2022   
    P1,  N=34, Active, not recruiting, 
    Greater understanding of the underlying blast genetics for infants with KMT2A-germline ALL and incorporation of immunotherapeutic approaches may enable a reduction in the intensity of chemotherapy while maintaining the excellent outcomes. Recruiting --> Active, not recruiting
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Journal, Residual disease, IO biomarker:  Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. (Pubmed Central) -  Dec 2, 2022   
    However, new approaches to target MRD in patients with T-ALL remain an unmet need. As our MRD detection assays become more sensitive and expanding novel therapeutics enter clinical development, the future of ALL therapy will increasingly utilize MRD as a criterion to either intensify or modify therapy to prevent relapse or de-escalate therapy to reduce treatment-related morbidity and mortality.
  • ||||||||||  Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion. (Pubmed Central) -  Dec 1, 2022   
    De novo lymphoid blastic-phase CML can therefore be difficult to differentiate from Philadelphia positive B-ALL due to their overlapping clinical and laboratory picture, implying the need to do myeloid compartment evaluation at the time of diagnosis. With recent progress in the treatment of Philadelphia positive B-ALL, including the role of transplant with the use of novel agents, a better characterization of this disease entity in retrospective and prospective trials is warranted.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial completion date, Trial primary completion date, Combination therapy:  AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) -  Dec 1, 2022   
    P3,  N=6720, Recruiting, 
    With recent progress in the treatment of Philadelphia positive B-ALL, including the role of transplant with the use of novel agents, a better characterization of this disease entity in retrospective and prospective trials is warranted. Trial completion date: Mar 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Sep 2029
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Haematopoietic Progenitor Cell Mobilisation Following Blinatumomab Therapy () -  Nov 29, 2022 - Abstract #ASH2022ASH_7834;    
    However, these patients are at risk of failed mobilisation and may benefit from pre-emptive strategies such as the use of plerixafor to optimise mobilisation success. Our relatively high rate of salvage reinfusion of autologous HPCs in ALL patients underlines the utility of universal back-up harvests for patients undergoing unrelated donor transplant.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Minimal Residual Disease Negativity after Blinatumomab Is Predictive of Survival in B-Cell Acute Lymphoblastic Leukemia: Data from a Real-Life Study () -  Nov 29, 2022 - Abstract #ASH2022ASH_7332;    
    Twenty-nine (87 %) patients received levetiracetam for seizure-prophylaxis.MRD was measured after each cycle by RT-qPCR with a sensitivity of 10-4 for clonal IgH and for BCR-ABL.As MRD response was considered clonal IgH or BCR-ABL < 10-4.Relapse-free survival (RFS) and overall survival (OS) were estimated by the Kaplan-Meier analysis and compared by the log-rank across the sub-groups using 95 % confidence intervals...MRD-responsive gain a significant survival advantage over non-responsive patients. This advantage was observed both for transplanted and non-transplanted patients.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    T-Cell Lymphocyte Kinetics As a Predictive Biomarker of Blinatumomab MRD Response in ALL-B Patients: A Single-Center Prospective Study () -  Nov 29, 2022 - Abstract #ASH2022ASH_7328;    
    By comparing the results according to disease-response (responders vs non-responders) the mean T1/T0 ratios were, respectively, 2.56 vs 1.51 for T4-eff (p = 0.008), 2.54 vs 1.67 for T8-eff (p = 0.016), 3.88 vs 1.09 for T4 IFNγ (p = 0.03), 2.89 vs 1.02 for T8 IFNγ (p = 0.03) (figure 1).CONCLUSIONPreliminary results evidence plausible association between T lymphocyte kinetics, including Inf-gamma production, and achievement of MRD negativity following the first blinatumomab cycle. Further studies with a larger population are needed to predict treatment response.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Improved Survival of Adolescents and Young Adults (AYA) Patients Aged 14-40 Years with First Relapse of Acute Lymphoblastic Leukemia Using Pediatric-Inspired Chemotherapy Salvage Protocol (R3 induction protocol) () -  Nov 29, 2022 - Abstract #ASH2022ASH_7237;    
    Background : Although survival of adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL) has improved using pediatric-inspired protocols, the outcomes of those who relapse remain poor using adult chemotherapy salvage-regimens that have historically incorporated high dose Ara-C based regimen, with long term-survival of less than 10%...The protocol consisted of vincristine (1.5mg/m2 IV D3,10,17,24); mitoxantrone ( 10mg/m2 IV d1 &2); PEG-asparaginase (1000 u/m2 IV d3 & 17); dexamethasone (10mg/m2 BID day d1-5 and d15-20); and intrathecal methotrexate (12mg d1 & d8) were identified...MRD-positive patients received blinatumomab followed by a transplant.Result s :The median age at relapse was 16 years (14-40 years), 88.2% of patients were B-cell ALL and 11.8% were T-cell ALL...At a median follow up of 4 years, OS was 47.3%.Conclusion :Compared to traditional adult-based chemotherapy regimens and antibody therapies used in relapsed ALL, the use of pediatric-inspired protocol (R3) in relapsed AYA-ALL patients showed favorable response rates and overall survival. Further trials are required of pediatric inspired salvage regimens, preferably incorporating antibody therapies in adult patients, especially in 1st relapse.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab () -  Nov 29, 2022 - Abstract #ASH2022ASH_7233;    
    Of the 115 cycles with CRS, 79 (69%) were followed by additional cycles of BLINA.CONCLUSIONCNS tox and CRS occurred in 33% and 35% of pts treated with BLINA and in 15% and 15% of BLINA cycles, respectively. With steroids and therapy modification, most pts who experienced toxicity were able to continue BLINA treatment while exhibiting similar outcomes to those without toxicity.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Outcomes in Hispanic Patients with Philadelphia-Negative and Philadelphia-like Acute Lymphoblastic Leukemia with the Use of Blinatumomab () -  Nov 29, 2022 - Abstract #ASH2022ASH_7197;    
    For MRD positive disease, median OS was not reached for either group (p-value=0.6).Conclusion : Both relapse disease and MRD+ disease are considered poor prognostic indicator. Our study highlights that blinatumomab can decrease survival gap for MRD + disease and relapse disease for ph-like Hispanic patients and decrease survival gap in MRD + ph-negative Hispanic patients when compared to patients who did not need blinatumomab
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Dermatologic Adverse Events in Acute Lymphocytic Leukemia Patients Treated with Bispecific T-Cell Engager Blinatumomab () -  Nov 29, 2022 - Abstract #ASH2022ASH_7191;    
    Blinatumomab DAEs may be more common in patients who experience CRS; this finding may support that DAEs are the result of increased circulating cytokines secondary to effective immune activation by blinatumomab. DAEs are mild and we recommend that patients with severe rash during blinatumomab infusion are carefully evaluated for other etiologies of rash.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Synribo (omacetaxine mepesuccinate) / Teva
    Homoharringtonine Is Effective in Treating T-ALL By Downregulating MCL-1 with Synergistic Effect When Combining with Venetoclax () -  Nov 29, 2022 - Abstract #ASH2022ASH_7173;    
    Moreover, the underlying mechanism of MCL-1 downregulation upon HHT treatment in triggering apoptosis needs further exploration. Nevertheless, our study provides a solid ground work of establishing the role of HHT and its combination with venetoclax in treating T-ALL.Acknowledgements: The work was supported by Health and Medical Research Fund (Project No: 07182526).
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal, CAR T-Cell Therapy:  Blinatumomab Prior to CAR-T Cell Therapy-A Treatment Option Worth Consideration for High Disease Burden. (Pubmed Central) -  Nov 27, 2022   
    To conclude, blinatumomab can effectively lower disease burden with fewer side effects than standard chemotherapeutics. Therefore, it may be a valid option for patients with high-disease burden prior to CAR-T cell therapy without clear evidence of compromising efficacy; however, further investigations are necessary.
  • ||||||||||  Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
    P2 data, Journal:  Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. (Pubmed Central) -  Nov 20, 2022   
    P2
    The chemotherapy-free combination of ponatinib and blinatumomab resulted in high rates of complete molecular response in patients with newly diagnosed and relapsed or refractory Ph-positive acute lymphoblastic leukaemia. Patients with newly diagnosed Ph-positive acute lymphoblastic leukaemia could be spared the toxicities associated with chemotherapy and the need for allogeneic haematopoietic stem-cell transplantation in first response.